Axa
PBYI icon

Axa’s Puma Biotechnology PBYI Stock Holding History

Axa’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-180,700
Closed -$1.85M – 1305
2020
Q4 		$1.85M Hold
180,700
– – 0.01% 865
2020
Q3 		$1.82M Hold
180,700
– – 0.01% 831
2020
Q2 		$1.89M Buy
+180,700
New +$1.87M 0.01% 838
2018
Q2 		– Sell
-21,314
Closed -$1.45M – 1393
2018
Q1 		$1.45M Buy
21,314
+10,667
+100% +$799K 0.01% 924
2017
Q4 		$1.05M Buy
+10,647
New +$1.19M ﹤0.01% 993

Other funds holding PBYI

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Axa's PBYI Position: Q1 2021 in Review

Axa sold out of Puma Biotechnology (PBYI) in Q1 2021, closing a stake of 180,700 shares — an estimated $1.85M sold.

Axa first reported a position in PBYI in Q4 2017 and held it in 5 quarters. The position peaked at $1.89M in Q2 2020. 118 funds tracked by Wall St. Rank hold PBYI as of Q1 2021.

  • Axa reported no remaining Puma Biotechnology position as of Q1 2021 after selling out during the quarter.
  • Axa sold 180,700 Puma Biotechnology shares in Q1 2021, an estimated $1.85M.
  • Axa first reported a position in Puma Biotechnology in Q4 2017 and held it in 5 quarters.
  • Axa's Puma Biotechnology position peaked at $1.89M in Q2 2020.
  • 118 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2021.

Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.